Raymond James raises Fulgent Genetics stock price target to $36 on strong performance
DexCom Inc. stock reached a 52-week low, closing at $56.44, as the company faces ongoing market challenges. This marks a significant point in the company’s performance, reflecting a 1-year price return of -15.8% and a steeper six-month decline of -30.39%. Despite the volatility, InvestingPro data shows DexCom remains profitable with 14.21% revenue growth over the last twelve months. The decline in stock value underscores the broader market pressures, with 19 analysts recently revising earnings expectations downward. Notably, InvestingPro analysis indicates the stock is currently undervalued, while maintaining a strong analyst consensus recommendation. Investors are closely monitoring DexCom’s strategies to navigate these challenges and improve its market standing.Want deeper insights? InvestingPro offers 10+ additional tips and a comprehensive Pro Research Report on DexCom, helping you make more informed investment decisions.
In other recent news, DexCom reported its third-quarter earnings for 2025, surpassing analysts’ expectations with an earnings per share (EPS) of $0.61 compared to the forecasted $0.57, resulting in a 7.02% earnings surprise. The company also exceeded revenue predictions, reporting $1.21 billion against an anticipated $1.18 billion, marking a 2.54% revenue surprise. Despite the positive earnings results, several analyst firms have adjusted their price targets for DexCom. Bernstein lowered its price target to $84, citing valuation concerns, while maintaining an Outperform rating. Piper Sandler reduced its target to $75 due to growth concerns but kept an Overweight rating. BTIG adjusted its target to $85, also citing growth concerns, while maintaining a Buy rating. Canaccord Genuity lowered its target to $99, attributing the change to quality costs, but continued to recommend a Buy rating. These developments reflect a cautious outlook from analysts despite DexCom’s strong quarterly performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.